Sathgen Therapeutics completa la dosificación de las dos primeras cohortes con MSP008-22

Posted on by

– Sathgen Therapeutics completa la dosificación de las dos primeras cohortes de voluntarios sanos con MSP008-22, un nuevo fármaco antiviral MSP008-22 es un nuevo candidato a fármaco que muestra una excelente eficacia contra diversos virus durante su desarrollo preclínico BOMBAY, La India,…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.